Apixaban NEW

Apixaban Nature Melting point 235-238 ° C Boiling point 770.5 ± 60.0 ° C (Predicted) Density 1.42 Storage conditions Refrigerator Solubility DMSO (Slightly, Hearted), Methanol (Slightly) Acid dissociation constant (pKa) 15.01 ± 0.20 (Predicted) Form Solid color WhitetoOff White Apixaban Use and synthesis method New oral Xa factor inhibitor Apixaban is a new oral Xa factor inhibitor jointly developed by Bristol Myers Squibb and Pfizer, The trade name is Alitol, which is a new type of oral anticoagulant drug. Apixaban can prevent thrombin formation and thrombosis by inhibiting Xa, an important coagulation factor. On April 26, 2007, Bristol Myers Squibb, together with Pfizer, announced the cooperative development of the new oral Anticoagulant Apixaban owned by Bristol Myers Squibb as an upgraded alternative to Warfarin. According to the cooperation agreement, Pfizer will pay $250 million in advance to Bristol Myers Squibb to bear 60% of the total development cost of Anticoagulant Apixaban (implemented from January 1, 2007), while Bristol Myers Squibb will bear the remaining 40%, so as to obtain the right to jointly develop and sell the drug. In May 2011, Apixaban took the lead in approving the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery in 27 EU countries, Iceland and Norway. On November 20, 2012, the European Commission approved elotal (Apixaban) for the prevention of stroke and Systemic circulation embolism in adult patients with non valvular atrial fibrillation (NVAF) with one or more risk factors. Subsequently, the Canadian Food and Drug Administration, Japan, and the US FDA approved Elotor? (Apixaban) is used for the prevention of stroke and Systemic circulation embolism in adult patients with non valvular atrial fibrillation (NVAF) with one or more risk factors. On April 12, 2013, the new anticoagulant drug ELIQUIS (Apixaban) jointly developed by Bristol Myers Squibb and Pfizer was officially announced to be launched in China. Elotol is a novel oral factor Xa inhibitor used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolism (VTE). Its launch provides a safe and effective new option for anticoagulation after orthopedic surgery in clinical practice, bringing good news to patients undergoing elective hip/knee replacement surgery in China. Clinical studies have confirmed that compared to subcutaneous injection of 40mg enoxaparin once a day, oral administration of erlitol twice a day is recommended? (Apixaban) 2.5mg is more effective in preventing venous thromboembolism events after hip or knee Joint replacement surgery, and will not increase the risk of bleeding.